Morepen Laboratories Limited · NSE:MOREPENLAB
Morepen Laboratories — Q3 FY2025 Earnings Presentation
31 slides from Morepen Laboratories's earnings presentation, Feb 6, 2025
Slide 1: Stock exchange filing cover letter
. illmEPEN C ~ ~ Year.rnf • ~ Excellence ~ Date: 06/02/2025 To, National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai- 400 051 Dalal Street, Mumbai- 400 001 Symbol: MOREPENLAB Scrip Code: 500288 Subject: Investor Pres
Slide 2: Investor Presentation Q3'FY25
-- -- -- -- -- -- -- investor PresentatioN Q3'FY25 MOREPEN LABORATORIES LIMITED
Slide 3: Safe Harbour
This investor presentation has been prepared for general information purposes in respect of Morepen Laboratories Limited (“Company”) together with its subsidiary, as applicable (together, with the Company, the “Group”) only, without regard to any specific objectives, suitability, financial situation
Slide 4: Index
INDEX 1 Consolidated View 2 Medical Devices 3 Pharma Business 4 Financial Overview
Slide 5: Consolidated View: Significant Increase in Margins
INDEX 1 Consolidated View Significant Increase In Margins Medical Devices and Pharma
Slide 6: Consolidated Highlights: Focus on Higher Margins
1 Consolidated 1\\0REPEN Rs. 2.39 Earnings Per Share (EPS) for the Nine Months Highlights: Focus on Higher Margins Q2 & Q3'FY25 Trailing Twelve Months (TTM) Rs. in Crores ~ 6.5% desc. Q2 FY’25 Q3'FY25 (§)0!§)®1@ 21.3% 22~oJ3®1@ Gross Revenue EBITDA [ Revenue ) ( 442.71 ) ( 458.12 ) Rs.1359.47 cr Rs.
Slide 7: Medical Devices
INDEX 2 Business Segments Medical Devices
Slide 8: Operational Performance: Medical Devices
1 Consolidated 10% Growth in Exports and 4% increase Operational Perfomance: in Domestic Revenue in 9M’FY25 Quarterly Revenue 9M Revenue • Overall demand for the quarter Rs. in Crores Rs. in Crores remained muted; there was a modest 1359 growth of 2.12% and 6.45%, 500 449 458 1400 1277 respectively,
Slide 9: Glucometers
Business Segments 2 Medical Devices 13.5mn Customer base with repeat purchase of strips every year Glucometers: Cumulative Glucometers Installed Gluco Strip Sold No. of Glucometers installed base * No. of Strips Sold in 9months** Cumulative no. Srips Sold* 14 (crores) 35 (crore) (crore) 12 30 200 1.
Slide 10: Blood Pressure Monitors
Business Segments 2 Medical Devices 6.65mn BP Monitors sold till 9M'FY25 Blood Pressure Monitors: with increasing health awareness No. of BP Monitors Sold Sales Revenue • Consistent growth in product demand Numbers in lakhs Rs. in Crores and expansion into new markets 10 9.48 80 73.45 • 100% manufac
Slide 11: Capacity Business Update
2 Medical Devices Capacity Expansion and backward Business Update: integration in full swing 120K sqft New Facility ready LED Screen Printing Plant started Expansion of BP Monitor Capacity
Slide 12: Global Business Update
2 Medical Devices Global Marketing and opportunities on Business Update: bring evaluated Arab Health, Dubai Jan’25 Product launch in Qatar, Doha Medica, Germany Nov’24 CT CH
Slide 13: Launch of New Mobile App: Morepen Sync
2 Medical Devices Sync Sync your vitals with Dr. Launch of New Mobile App: Morepen Sync Mobile App ~ orepen s,~ Your Total Logs Last Recorded 12 Dec 2024 Take control of your 24 10 16 Total Blood Glucose logs To!JI Blood Pressure logs Tot.l l We gh! logs health and wellness with T RACK YOUR HEALTH D
Slide 14: Pharma Business
INDEX 3 Pharma Business Pharma Business API, Finished Dosages, Rx and oTC
Slide 15: Operational Performance: Pharma Business
Business Segments APIs and Finished Dosages 3 Pharma Business 1\\0REPEN 10% Increase in Exports of High Operational Perfomance: Value APIs in 9M’FY25 Quarterly Revenue 9M Revenue Rs. in Crores Rs. in Crores Rs. in Crores 1000 923 966 500 350 341 335 500 455 300 800 5% 10% 400 250 600 300 200 150 400
Slide 16: Business Segments: Consolidated Revenue
1 Consolidated 29% 9M revenue share from Medical Business Segments: Consolidated Revenue of Rs. 901 cr, up 9% Devices as compared to 26% in FY24 Pharma Business Medical Devices Rs. in Crores Rs. in Crores 1000 966 400 394 Devices 800 29% 300 600 200 9M 400 335 123 100 Pharma 200 71% 0 0 revenue spli
Slide 17: Operational Performance: Medical Devices Revenue
Business Segments 2 Medical Devices 11% Increase in 9M revenue with Operational Perfomance: increased installed Gluometers base Quarterly Revenue 9M Revenue Rs. in Crores Rs. in Crores 394 140 400 354 others 123 11% BP Monitors 3.7% 120 107 15% 18.6% 300 100 80 200 60 9M 40 100 20 Glucometers 0 0 77
Slide 18: Operational Performance: APIs and Finished Dosages
Business Segments APIs and Finished Dosages 3 Pharma Business 1\\0REPEN 75% Business share of API from Operational Perfomance: long-term cusotmers Quarterly Revenue 9M Revenue Rs. in Crores Rs. in Crores 342 335 966 341 350 1000 923 500 307 300 RX+OTC 86 252 11% 92 800 233 400 8.4% 8.4% 250 RX+OTC 3
Slide 19: API Business: Exports to Over 80 Countries
Business Segments API Business 3 Pharma Business 1\\0REPEN 9% Increase in exports with consistent repeat orders Exporting to over 80 Countries: ,,..,~............ ,, - •7. ~ ~.~ . . S.America USA 4.4% 14.8% Over Over India 500 200 70% 29.7% 9M Europe 22% Customers Customers in India Exports Worldwid
Slide 20: API Project Updates: Capacity
3 API Business 1\\0REPEN 510KL API Capacity ready, up from 400Kl Project Updates: one year ago P-8 Plant Expansion Completed P-8 Ready for Production P-9 Expansion Started
Slide 21: API Project Updates: QC Lab Expansion
3 API Business 1\\0REPEN 50KL API Capacity added making Project Updates: available API capacity 450KL QC Lab Expansion QC Lab Expansion QC Lab Expansion
Slide 22: API International Outreach
3 API Business 1\\0REPEN 50KL API Capacity added making available API capacity 450KL International Outreach: CPHI, Milan CPHI, India CPHI, China
Slide 23: Consumer Business: Weight Management Launches
3 Consumer Business Dr. Morepen $23bn Lightlife® Market Size of the Weight Management market in India New Products Launched: 360° s ustamable • Weight M anagement Award-winning Slimbiome® from the UK and Intelicaps Probiotics from Belgium Pre-meal Drinks On the Go Meal Patented Igredients Dr. Morepe
Slide 24: New Rx Medicines Launched
3 Rx Medicines 1\\0REPEN New Product to prevent for the heart New Products Lauched: stroke and liver sclerosis Ticapen 90mg UdoFix 300 UdoFix 150 Ticagrelor Tablets IP 90 mg Ticapin°so mg Ursoaeoxyc~olic Acia loolets I~300 mg Ursodeoxycholic Acid Tablets IP 150 mg •· ·•· R-ct51l.1crl T1cagrelor Tabl
Slide 25: Awards and Accolades
3 General 1\\0REPEN Awards Awards and Accolades for Awards and Accolades: Operational excellence Visionary Entrepreneur 2024 Top 50 Supply Chain & Logistics Dr. Morepen- Brand Icon of 2024 Top SO Supply c~ain & Logistics -'"lli~tlOI (~Om•
Slide 26: Bubble Chat Season 2
3 General 1\\0REPEN 32 Episodes of a talk show with Bubble Chat Season 2 was completed successfully: Industry leaders Live Monthly Chat Show with live YouTube streaming Dr. Ram Charan Mr. Shiv Khera Dr. Praveen Gupta Mr. Kush Kapoor Mrs. Shalu Suri Season -2 Click here to join Lt. Rita Gangwani Mr.
Slide 27: Financial Overview: Improving EBITDA Margins and PAT
INDEX 4 Financial Overview Improving EBITDA Margins and PAT
Slide 28: Quarterly Performance
4 Financial Overview 24% Lower EBITDA on account of input cost Quarterly Performance: pressure and expenses increase Rs. in Crores Rs. in Crores Gross Revenue EBITDA EBITDA %age 500 458 60 54.63 449 14 12.18% 2% 50 41.48 12 400 9.05% 40 24% 10 300 8 30 200 20 6 4 100 10 2 0 0 0 Q3'FY24 Q3'FY25 Q3'FY
Slide 29: 9 Months Performance
4 Financial Overview 21% EBITDA growth on account of 9 Months Performance: increase in sales revenues Rs. in Crores Rs. in Crores Gross Revenue EBITDA EBITDA %age 200 1359 146 12 10.71% 1400 1277 150 1200 120 10 9.40% 6.52% 21% 1000 8 100 800 6 600 50 4 400 200 2 0 0 0 9M'FY24 9M'FY25 9M'FY24 9M'FY2
Slide 30: 9 Months Profitability
4 Financial Overview 44% Increase in Profit after tax in 9M on 9 Months Profitability: with improved EBITDA Rs. in Crores Rs. in Crores Rupees Profit Before Tax (PBT) Profit After Tax (PAT) Earning Per Share (Rs.) 140 129.39 97.71 3.0 2.39 100 120 39% 44% 2.5 100 93.21 80 67.88 1.85 2.0 80 60 1.33 6
Slide 31: Thank you
Thank you www.morepen.com
Morepen Laboratories — Q3 FY2025 Earnings Presentation on 6ix